MK-677 (ibutamoren) is a research-only compound, not an approved medicine. The pattern below is commonly cited and anecdotal — not medically established. It is provided for education, not as a personal protocol.
Overview
MK-677 is an orally active growth-hormone secretagogue — a small molecule taken by mouth rather than an injected peptide. There is no regulator-approved schedule, so any figures come from community reports rather than clinical labeling.
Commonly cited pattern
Reported figures vary and should be treated as unverified:
- A commonly cited amount is roughly 10-25 mg orally, once daily.
- It is usually described as taken once per day because it is long-acting; some sources take it at night, others in the morning.
- These numbers are anecdotal and not medically established; there is no validated schedule.
Because effects on appetite and glucose can be pronounced, a start-low approach is the cautious framing.
How it is taken
Unlike injectable secretagogue peptides, MK-677 is taken orally, so there is no reconstitution or syringe math. Its oral bioavailability is what allows once-daily dosing, and the specifics depend on the product's formulation.
Why it is long-acting
MK-677 is comparatively long-acting, which is why it is framed around once-daily, sustained GH stimulation rather than mimicking the body's natural pulses. As with other secretagogues, continued exposure can blunt the response over time (tachyphylaxis).
Why oversight matters
MK-677 affects glucose handling, insulin sensitivity, and fluid retention, and it has no approved safety label. Those metabolic effects make unsupervised use especially inadvisable. Any real-world decision belongs within controlled research under qualified supervision.